This study evaluated the impact of the sodium-glucoseLlinked co-transporter-2 inhibitor, empagliflozin, on cardiac function and structure in a nondiabetic model of heart failure with preserved ejection fraction in the deoxycorticosterone acetate salt-sensitive rat. This study concluded that the sodiumglucoseLlinked co-transporter-2 inhibitor, empagliflozin, in a nondiabetic model of heart failure with preserved ejection fraction improved cardiac diastolic function and reduced wall stress primary through a reduction in cardiac preload, and also altered hemodynamics.
. Although the importance of these trials cannot be overstated, their outcomes are mostly unexpected. It is uncertain whether this drug class may provide similar benefit in both HFpEF and HFrEF or in only 1 of these conditions. Moreover, the magnitude of the effect of this therapy on HF hospitalization and the rapidity of its onset suggest that the cardioprotective properties of SGLT2is are greater than their ability to lower glucose. These findings have led not only to speculation as to how this antihyperglycemic drug class might exert its salutary effects but have also led to consideration that they may be also effective in the nondiabetic setting. Nordisk, and Janssen. Dr. Advani has received research support from AstraZeneca and Boehringer Ingelheim. Dr. Gilbert is a shareholder in Certa, OccuRx, and Fibrocor Therapeutics; has received research grants from AstraZeneca and Boehringer Ingelheim; has received travel support from AstraZeneca; and has received honoraria for speaking engagements and ad hoc participation in advisory boards from AstraZeneca, Boehringer Ingelheim, and Janssen. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Connelly et al.
Empagliflozin Improves Diastolic Function F E B R U A R Y 2 0 1 9 : 2 7 -3 7 silicone rubber (5) . Implanted rats then received 1% sodium chloride as drinking water, whereas uninephrectomy (UNX) rats were given tap water.
One week later, rats were randomized to receive either empagliflozin mixed in chow (0.35 mg/g, gift of
Boehringer Ingelheim, Ingelheim, Germany) or a control diet that coincided with DOCA implantation.
Four weeks after DOCA implantation, rats underwent echocardiography and cardiac catheterization.
All procedures were performed in the research vivarium under anesthesia using 2.5% isoflurane.
Systolic blood pressure was measured in conscious animals using an occlusive tail-cuff plethysmograph (Powerlab, ADInstruments, Colorado Springs, Colorado) (6) . Before the animals were killed, they were housed in metabolic cages, and 24-h urine collections were obtained for measurement of glucose, sodium, and ß-OH butyrate excretion. Animals then underwent echocardiography and cardiac catheterization as described in the following. After these procedures, animals were killed, and their hearts were harvested for structural and molecular measurements. Tibial length was measured to provide a morphometric index for cardiac hypertrophy and lung weight (7).
All animals were housed with 2 per cage at the St. ECHOCARDIOGRAPHY. Transthoracic echocardiography was performed, as previously described (8), under light anesthesia (1% isoflurane supplemented with 100% oxygen) before the animals were killed.
Images were acquired using a high-frequency ultra- CARDIAC CATHETERIZATION. Cardiac catheterization was performed as previously published (6) .
Briefly, rats were anesthetized with 2% isoflurane, intubated using a 14-gauge catheter, and ventilated were then calculated, as previously reported (10).
HISTOPATHOLOGY. The extent of cardiac myocyte hypertrophy was determined on hematoxylin and eosinÀstained sections, as previously reported (7). In brief, stained sections were scanned digitally by high resolution microscopy (Ultra-Resolution Digital Scanning System, Aperio Technologies Inc., Vista, California), and images were analyzed with NDP view2 software (Hamamatsu Photonics, Hamamatsu City, Japan). Cardiac myocytes with elliptical nuclei in the transverse section were selected. Diameter measurements were taken membrane-to-membrane across the narrowest point crossing the nucleus. The average diameter of 30 to 50 myocytes per animal was measured, as previously described (11).
WESTERN BLOTTING. For preparation of cytosolic fraction, heart tissues were minced and homogenized in homogenization buffer containing sucrose (250 mM), Tris-hydrogen chloride (10 mM),
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increased heart weight and lung weight when indexed to tibial length, which was reduced with empagliflozin ( Table 1) . Both water intake and urine output were increased in proportion to each other in rats that had received empagliflozin in both control and DOCA salt settings.
LABORATORY PARAMETERS. Hematocrit and hemoglobin were lower in DOCA salt animals compared with control animals, and although these were not normalized to levels seen in control rats, hematocrit and hemoglobin were both substantially higher among DOCA salt rats that received empagliflozin ( Table 2) . Plasma sodium and 24-h urinary sodium excretion were increased in DOCA salt rats, although neither was affected by empagliflozin administration ( Table 2) .
Regardless of assignment to control or DOCA salt groups, animals that received empagliflozin showed substantial glucosuria, and, although still within the normoglycemic range, plasma glucose in DOCA salt rats was lower in those that received empagliflozin ( Table 2) . Urinary excretion of ß-OH-butyrate was higher in DOCA salt animals than that in control animals and did not differ U ¼ urine; other abbreviations as in Table 1 .
FIGURE 2 Representative Echocardiograms
Representative echocardiograms (M-MODE) in (A) UNX þ control, (B) UNX þ empagliflozin, and (C) UNX þ DOCA þ control, and (D) UNX þ DOCA þ empa. Both left ventricular internal diameter systole (LVIDs) and wall thickness were reduced by empa in DOCA salt rats. *p < 0.05 versus UNX treated with vehicle. LVIDd ¼ left ventricular internal diameter diastole; other abbreviations as Figure 1 .
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Empagliflozin Improves Diastolic Function according to treatment assignment to empagliflozin or vehicle ( Table 2) .
ECHOCARDIOGRAPHY. DOCA salt rats demonstrated preserved EF with increased wall thickness and LV mass compared with control rats (Figure 2 , Table 3 ).
Empagliflozin therapy reduced LV end-systolic dimension, LV mass, and posterior wall thickness (Table 3) .
CONDUCTANCE CATHETERIZATION. A high-fidelity LV pressure manometer was used to assess diastolic function. DOCA salt administration prolonged Tau and reduced dp/dt min , which indicated impaired diastolic relaxation; these abnormalities were both ameliorated by empagliflozin ( Table 3) . Similarly, wall stress that was increased in DOCA salt rats was reduced with empagliflozin. In contrast, late diastolic relaxation, as assessed by the end-diastolic pressureÀvolume relationship, was not increased by DOCA salt and was unaffected by empagliflozin (Table 3 , Figure 3 ). Empaglifozin treatment had no effect on collagen 1/III or ANP mRNA ( Figure 5 ).
Because of the surprising absence of altered protein expression in key cardiac calcium handling proteins, we went on to assess whether the observed functional benefits were secondary to improved myocardial energetics. As a result, we performed RTq polymerase chain reaction on a panel of genes known to be involved in metabolism. UNX þ DOCA had minimal effect on gene expression of the metabolic 
FIGURE 3 Steady-State PressureÀVolume Loops
Empa-treated UNX þ DOCA salt animals display a leftward shift with a reduction in end-diastolic volume (blue curve) compared with the UNX þ DOCA salt control animals (gray curve). Abbreviations as in Figures 1 and 2 .
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Empagliflozin Improves Diastolic Function (A to D) Representative hematoxylin and eosin and (E to H) picrosirius red stained sections. Hearts of UNX þ DOCA salt rats showed evidence of (I) myocyte hypertrophy, together with both (J and K) perivascular and interstitial fibrosis. Empa reduced cardiomyocyte size in UNX þ DOCA animals but had no effect on either interstitial or perivascular fibrosis. n ¼ 7 to 8 in UNX control and UNX empa groups; n ¼ 16 and 15 in DOCA control and empa groups, respectively. *p < 0.05 treated with UNX þ control. †p < 0.05 treated with UNX þ DOCA þ control. CSA ¼ cross-sectional area; other abbreviations as in Figure 1 .
increase in wall stress, there is an increase in wall thickness (i.e., hypertrophy) that allows the workload to be shared among a greater number of sarcomeric units. Although initially beneficial, the resultant changes in the pressureÀvolume relationship lead not only to cardiomyocyte hypertrophy but also to interstitial fibrosis, impaired relaxation, and ultimately HFpEF.
In contrast to vehicle-treated rats, the present study found that the administration of empagliflozin Hearts of DOCA salt rats showed evidence of atrial natriuretic peptide (ANP) activation, together with increased collagen I (Col I) and III mRNA. Empa had no effect on either ANP, or Col I or III mRNA. n ¼ 8 for control (Cont) UNX; n ¼ 7 for UNX empa; n ¼ 14 for control DOCA; n ¼ 13 for empa DOCA. *p < 0.05 compared to UNX animals treated with UNX þ control. RPL13a ¼ ribosomal protein L13A housekeeping gene; other abbreviations as in Figure 1 .
Empagliflozin Improves Diastolic Function Finally, although we did not find any statistical differences in systolic blood pressure, as shown in KEY WORDS diastole, heart failure with preserved ejection fraction, sodiumglucoseÀlinked co-transporter-2 inhibitor, systole APPENDIX For supplemental tables and figures, please see the online version of this paper.
